Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 212Pb-TCMC-Trastuzumab |
Synonyms | |
Therapy Description |
212Pb-TCMC-Trastuzumab, a combination of trastuzumab, the chelating agent TCMC, and lead Pb 212, targets and destroys HER2 positive cells through cytotoxic radiation (PMID: 27906723). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
212Pb-TCMC-Trastuzumab | HER2 (ERBB2) Antibody 76 | 212Pb-TCMC-Trastuzumab, a combination of trastuzumab, the chelating agent TCMC, and lead Pb 212, targets and destroys HER2 positive cells through cytotoxic radiation (PMID: 27906723). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|